Montelukast Teva (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1 found on airway smooth‑muscle cells, mast cells and eosinophils. This antagonism prevents leukotrienes, especially leukotriene D4, from triggering bronchoconstriction, mucus production and inflammatory cell recruitment, thereby easing airway narrowing and allergic inflammation.

The prescribing clinician determines the dose based on the patient’s age, weight, specific indication and clinical response. Standard dosing recommendations exist for adults and children, but the final regimen is individualized and should follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy are limited, and the drug is generally prescribed only when the potential benefit outweighs any possible risk to the fetus. During breastfeeding, only limited information is available; clinicians should evaluate the risk‑benefit profile for the infant before continuing therapy.

To place an order, submit an enquiry on the Montelukast Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, whereas inhaled corticosteroids target a broader range of inflammatory pathways. Montelukast is taken orally once daily and is particularly useful for patients who cannot tolerate inhaled steroids or need additional control for exercise‑induced symptoms. However, inhaled corticosteroids generally provide stronger anti‑inflammatory effects for persistent asthma.

Montelukast Teva tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Montelukast Teva is supplied as oral tablets that are swallowed whole with water. The medication can be taken with or without food, and it is usually taken once daily at the same time each day to maintain consistent blood levels. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious adverse events associated with Montelukast include severe allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric effects like depression, suicidal thoughts or behavior. Hepatic dysfunction manifested by elevated liver enzymes and rare blood disorders such as neutropenia may also occur. Prompt medical attention is required if any of these symptoms develop.

Montelukast Teva should be avoided in individuals with known hypersensitivity to montelukast or any of the tablet excipients. Caution is also advised for patients with severe hepatic impairment, active psychiatric illness, or those taking medications that strongly induce its metabolism. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.